- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Alzheimer's diagnosis new Guidelines
Overview
Recently, at the International Alzheimer's Congress (AAIC) in Amsterdam, new guidelines for diagnosing Alzheimer's disease developed by clinicians and researchers from around the world were presented. In these criteria, the disease is diagnosed in the clinic through the use of blood biomarkers, just as with other major diseases such as diabetes and cardiovascular disease.
New research shows that many people with cognitive symptoms want to know whether they are in the early stages of Alzheimer's. A diagnosis enables patients to take more control over the next phase of their lives. The desire to know whether or not you have Alzheimer's disease makes the use of blood biomarkers so relevant, it is also the gateway to treatment.
The Swedish research, presented at the ADPD conference in March, has shown that biomarkers can be more reliable than the analysis of a primary care physician. In addition, the blood test is much less stressful for the patient than the current method. Currently, Alzheimer's is diagnosed through the analysis of cerebrospinal fluid, acquired through an invasive lumbar puncture, or via an expensive PET scan. It is believed that both of these methods will soon also be less necessary in the diagnosis of Alzheimer's.
The new guidelines were developed by an international committee of practitioners and researchers on behalf of the International Alzheimer's Association and the American National Institute on Aging. Previously, Alzheimer's was defined by identifying brain pathology and cognitive decline with which the disease manifested itself. In the new guideline, the disease is diagnosed using biomarkers. More biomarkers with excellent diagnostic performance have been developed and clinically validated in recent years. And more are coming.
Reference: Charlotte Teunissen et al, AMSTERDAM UNIVERSITY MEDICAL CENTERS
Speakers
Isra Zaman
B.Sc Life Sciences, M.Sc Biotechnology, B.Ed